- Beranda
- Komunitas
- Entertainment
- The Lounge
Sinovac, Dulu Dicerca Sekarang Dipuja
TS
powerpunk
Sinovac, Dulu Dicerca Sekarang Dipuja
Selamat pagi, siang, sore, petang, dan malam kawan - kawan kaskuser semua yang baik hati. Bertemu kembali di thread sederhana ane.
Awal pandemi, semua orang ketakutan. Terbukti, semua produk yang berfungsi untuk pencegahan, seperti masker, hand sanitizer, disinfectan langka. Semua orang berharap obat atau vaksin segera ditemukan dan pandemi segera berlalu. Saat vaksin benar - benar sudah ditemukan dan siap digunakan, banyak yang nyinyir. Bilang pandemi memang sengaja dibuat sehingga vaksin cepat ditemukan. Bilang kalau vaksin itu haram dan tak layak pakai. Dan seterusnya, dan seterusnya.
Masyarakat terbelah, ada yang pro vaksin, tapi tak sedikit juga yang kontra. Puncaknya, saat pemerintah secara resmi memesan vaksin Sinovac buatan Tiongkok. Banyak masyarakat, utamanya netizen mencibir dan mempertanyakan kualitas dari vaksin ini. Banyak yang menganggap pemerintah terlalu pro Tiongkok sehingga untuk urusan vaksin pun harus pesan dari sana. Padahal, banyak negara lain, yang menurut pandangan mereka lebih layak dan lebih berkualitas vaksinnya dibanding vaksin Sinovac buatan Tiongkok.
Meski, Pak Presiden sendiri akhirnya menjadi orang pertama di Indonesia yang divaksin dengan vaksin Sinovac, tapi tetap saja langkah presiden tak serta merta membuat publik percaya. Ada yang bilang presiden kala itu disuntik dengan vitamin, bukan dengan vaksin Sinovac. Ada juga yang ngomong suntikan yang dipakai sudah dimodifikasi dan sebenarnya tak ada cairan yang disuntikkan ke lengan Jokowi.
Seiring waktu, dari satu ke tempat yang lain, berkeliling Indonesia, Pak Jokowi mengawal pelaksanaan vaksinasi menggunakan vaksin Sinovac ini. Disisi lain, sebagai bentuk upaya mempercepat pelaksaan vaksin dan terbentuknya herd immunity, pemerintah memilih opsi untuk menambah pasokan vaksin dari Inggris bernama vaksin Astrazeneca. Sebagai vaksin yang diproduksi oleh perusahaan dari negara barat, vaksin ini lebih dipercaya oleh masyarakat. Apalagi efikasi vaksin ini lebih tinggi ketimbang efikasi dari vaksin Sinovac buatan Tiongkok.
Beberapa bulan setelah pelaksanaan vaksin menggunakan vaksin Astrazeneca, banyak isu seputar vaksin ini. Banyak yang mengeluhkan efek samping paska divaksin. Di beberapa negara diluar Indonesia juga ada berita bahwa vaksin ini menyebabkan penggumpalan darah. Bahkan, penggunaannya sempat dihentikan. Puncaknya, saat seorang warga di Jakarta Timur meninggal dunia satu hari paska di suntik vaksin Astrazeneca. Meski belum diketahui secara pasti apakah ada kaitan antara kematiannya dengan vaksin Astrazeneca, sebagai bentuk kehati - hatian, pemerintah memutuskan untuk menghentikan terlebih dahulu penggunaan vaksin Astrazeneca khusus batchyang sama dengan batch yang disuntikkan pada warga Jakarta Timur yang meninggal tadi.
Spoiler for :
Sebaliknya, setelah dipakai beberapa bulan, vaksin Sinovac semakin menunjukkan kualitasnya. Meski awalnya sempat dipandang sebelah mata karena dianggap sebagai vaksin yang kurang berkualitas, nyatanya sekarang vaksin ini mampu mencegah kematian akibat virus covid 19 hingga 100%. Bukan hanya itu, vaksin ini juga diklaim mampu mencegah rawat inap pasien covid hingga 98%. Juga, terbukti mencegah infeksi akibat virus covid hingga 94%. Sebuah angka yang cukup tinggi. Dan yang terakhir, vaksin ini juga paling sedikit menimbulkan efek samping.
Angka - angka tersebut diatas tentu saja bukan angka yang ditulis asal - asalan. Tapi berdasarkan pengamatan terhadap 25.374 petugas kesehatan di Jakarta yang sudah menerima dua dosis vaksin Sinovac. Hasilnya sesuai data diatas, sangat menggembirakan. Ini merupakan harapan baru bagi Indonesia agar segera keluar dari pandemi ini. Dan sebagai penutup, ane sempat membuat polling kecil - kecilan dikalangan teman - teman dekat ane dengan pertanyaan terbuka, yaitu jika disuruh memilih vaksin Sinovac atau Astrazeneca, 90% diantaranya memilih Sinovac. Mungkin polling ini tidak bisa mewakili pandangan masyarakat Indonesia secara umum, hanya saja karena Sinovac memang tidak banyak menyebabkan efek samping, maka vaksin ini lebih dipilih.
So, buat Gansis yang punya pendapat lain atau pengalaman terkait dengan vaksin, baik vaksin Sinovac maupun Atrazeneca, silakan tinggalkan jejak di kolom komentar.
Disclaimer : Asli tulisan TS
Referensi : Inidan Ini
Sumur Gambar : Om Google
Diubah oleh powerpunk 29-05-2021 06:23
rony25 dan 51 lainnya memberi reputasi
50
16K
389
Guest
Tulis komentar menarik atau mention replykgpt untuk ngobrol seru
Tampilkan semua post
otce
#65
Sinovac efikasinya rendah, wong dari direktur china disease controlnya aja yang mengakui:
Chinese vaccines’ effectiveness low, official admits
Efficacy of a coronavirus vaccine from Sinovac – one of main jabs – has been found to be as low as 50.4 percent by researchers.
Updated:
12 Apr 2021
03:57 AM (GMT)
In a rare admission of the weakness of Chinese coronavirus vaccines, the country’s top disease control official has said their effectiveness is low and the government is considering mixing them in an attempt to boost their efficacy.
Chinese vaccines “don’t have very high protection rates”, Gao Fu, the director of the China Centers for Disease Control, said at a conference on Saturday in the southwestern city of Chengdu.
“It’s now under formal consideration whether we should use different vaccines from different technical lines for the immunisation process,” Gao said without specifying whether that would include foreign-made vaccines.
He said changing the number of doses and the length of time between doses were also a “definite” solution to efficacy issues.
The overall effectiveness rate of Sinovac, the most well-known of the four vaccines developed in China for public use, was found to be as low as 50.4 percent during late stage trials in Brazil although the performance was better in Indonesia and Turkey.
The developer has not yet released final data for peer review, but a paper published by Brazilian researchers on Sunday ahead of peer review found two injections of the vaccine when given shorter than three weeks apart, was 49.1 percent effective, below the 50 percent threshold set by World Health Organization.
China’s drugsmakers have relied on traditional methods to develop vaccines against the coronavirus [File: Thomas Peter/Reuters]
Data from a small subgroup showed that the efficacy rate increased to 62.3 percent when the doses were given at intervals of three weeks and longer.
In comparison, the vaccine made by Pfizer-BioNTech – also a two dose regimen – has been found to be 97 percent effective.
Beijing has yet to approve any foreign vaccines for use in China, where the coronavirus emerged in late 2019.
Gao gave no details of possible changes in strategy but mentioned mRNA, a previously experimental technique that was used to develop the Pfizer jab and by some other Western vaccine developers. China’s drug-makers have relied on traditional technology.
“Everyone should consider the benefits mRNA vaccines can bring for humanity,” Gao said. “We must follow it carefully and not ignore it just because we already have several types of vaccines already.”
Play Video
mRNA
Gao previously raised questions about the safety of mRNA vaccines. He was quoted by the official Xinhua news agency as saying in December he could not rule out negative side effects because they were being used for the first time on healthy people.
Chinese state media and popular health and science blogs also have questioned the safety and effectiveness of the Pfizer-BioNTech vaccine, which uses mRNA.
As of April 2, some 34 million people have received the two doses required by Chinese vaccines and about 65 million received one, according to Gao.
Experts say mixing vaccines, or sequential immunisation, might boost effectiveness rates. Trials around the world are looking at mixing vaccines or giving a booster shot after a longer time period.
Researchers in Britain are studying a possible combination of the Pfizer-BioNTech and AstraZeneca vaccines.
China has shipped millions of its vaccines abroad, and officials and state media have fiercely defended the shots while calling into question the safety and logistics capabilities of other vaccines.
“The global vaccine protection rate test data are both high and low,” Gao told state tabloid Global Times on Sunday.
“How to improve the protection rate of vaccines is a problem that requires global scientists to consider,” Gao said, adding that mixing vaccines and adjusting immunisation methods are solutions that he had proposed.
Gao also rejected claims by some media reports that he said Chinese COVID-19 vaccines have a low protection rate, telling Global Times that it was “a complete misunderstanding.”
Source
Chinese vaccines’ effectiveness low, official admits
Efficacy of a coronavirus vaccine from Sinovac – one of main jabs – has been found to be as low as 50.4 percent by researchers.
Updated:
12 Apr 2021
03:57 AM (GMT)
In a rare admission of the weakness of Chinese coronavirus vaccines, the country’s top disease control official has said their effectiveness is low and the government is considering mixing them in an attempt to boost their efficacy.
Chinese vaccines “don’t have very high protection rates”, Gao Fu, the director of the China Centers for Disease Control, said at a conference on Saturday in the southwestern city of Chengdu.
“It’s now under formal consideration whether we should use different vaccines from different technical lines for the immunisation process,” Gao said without specifying whether that would include foreign-made vaccines.
He said changing the number of doses and the length of time between doses were also a “definite” solution to efficacy issues.
The overall effectiveness rate of Sinovac, the most well-known of the four vaccines developed in China for public use, was found to be as low as 50.4 percent during late stage trials in Brazil although the performance was better in Indonesia and Turkey.
The developer has not yet released final data for peer review, but a paper published by Brazilian researchers on Sunday ahead of peer review found two injections of the vaccine when given shorter than three weeks apart, was 49.1 percent effective, below the 50 percent threshold set by World Health Organization.
China’s drugsmakers have relied on traditional methods to develop vaccines against the coronavirus [File: Thomas Peter/Reuters]
Data from a small subgroup showed that the efficacy rate increased to 62.3 percent when the doses were given at intervals of three weeks and longer.
In comparison, the vaccine made by Pfizer-BioNTech – also a two dose regimen – has been found to be 97 percent effective.
Beijing has yet to approve any foreign vaccines for use in China, where the coronavirus emerged in late 2019.
Gao gave no details of possible changes in strategy but mentioned mRNA, a previously experimental technique that was used to develop the Pfizer jab and by some other Western vaccine developers. China’s drug-makers have relied on traditional technology.
“Everyone should consider the benefits mRNA vaccines can bring for humanity,” Gao said. “We must follow it carefully and not ignore it just because we already have several types of vaccines already.”
Play Video
mRNA
Gao previously raised questions about the safety of mRNA vaccines. He was quoted by the official Xinhua news agency as saying in December he could not rule out negative side effects because they were being used for the first time on healthy people.
Chinese state media and popular health and science blogs also have questioned the safety and effectiveness of the Pfizer-BioNTech vaccine, which uses mRNA.
As of April 2, some 34 million people have received the two doses required by Chinese vaccines and about 65 million received one, according to Gao.
Experts say mixing vaccines, or sequential immunisation, might boost effectiveness rates. Trials around the world are looking at mixing vaccines or giving a booster shot after a longer time period.
Researchers in Britain are studying a possible combination of the Pfizer-BioNTech and AstraZeneca vaccines.
China has shipped millions of its vaccines abroad, and officials and state media have fiercely defended the shots while calling into question the safety and logistics capabilities of other vaccines.
“The global vaccine protection rate test data are both high and low,” Gao told state tabloid Global Times on Sunday.
“How to improve the protection rate of vaccines is a problem that requires global scientists to consider,” Gao said, adding that mixing vaccines and adjusting immunisation methods are solutions that he had proposed.
Gao also rejected claims by some media reports that he said Chinese COVID-19 vaccines have a low protection rate, telling Global Times that it was “a complete misunderstanding.”
Source
Diubah oleh otce 30-05-2021 04:09
eyefirst2 dan 4 lainnya memberi reputasi
5
Tutup